Test-Brinzolamide 1% Ophthalmic suspension — Competitive Intelligence Brief

Test-Brinzolamide 1% Ophthalmic suspension (Test-Brinzolamide 1% Ophthalmic suspension) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Carbonic anhydrase inhibitor. Area: Ophthalmology.

phase 3 Carbonic anhydrase inhibitor Carbonic anhydrase II Ophthalmology Small molecule

Target snapshot

Test-Brinzolamide 1% Ophthalmic suspension (Test-Brinzolamide 1% Ophthalmic suspension) — Actavis Inc.. Test-Brinzolamide 1% Ophthalmic suspension works by reducing intraocular pressure by increasing the outflow of aqueous humor.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Test-Brinzolamide 1% Ophthalmic suspension TARGET	Test-Brinzolamide 1% Ophthalmic suspension	Actavis Inc.	phase 3	Carbonic anhydrase inhibitor	Carbonic anhydrase II
Azopt	BRINZOLAMIDE	Novartis	marketed	Carbonic Anhydrase Inhibitor [EPC]	carbonic anhydrase II	1998-01-01
Low Dose Acetazolamide	Low Dose Acetazolamide	University of Utah	marketed	Carbonic anhydrase inhibitor	Carbonic anhydrase II
Dorzolamide-timolol-brimonidine and latanoprost	Dorzolamide-timolol-brimonidine and latanoprost	Laboratorios Sophia S.A de C.V.	marketed	Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, alpha-2 agonist, and prostaglandin analog	Carbonic anhydrase II, beta-2 adrenergic receptor, alpha-2A adrenergic receptor, prostaglandin F receptor
Dorzolamide-timolol and latanoprost	Dorzolamide-timolol and latanoprost	Laboratorios Sophia S.A de C.V.	marketed	Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, and prostaglandin F analog	Carbonic anhydrase II (dorzolamide), beta-1 and beta-2 adrenergic receptors (timolol), prostaglandin F receptor (latanoprost)
tafluprost and dorzolamide/timolol	tafluprost and dorzolamide/timolol	Aristotle University Of Thessaloniki	marketed	Prostaglandin analogue / carbonic anhydrase inhibitor / beta-blocker combination	Prostaglandin F receptor (FP receptor), carbonic anhydrase II, beta-1 and beta-2 adrenergic receptors
Xalatan+Cosopt	Xalatan+Cosopt	University of Turin, Italy	marketed	Prostaglandin analog + carbonic anhydrase inhibitor + beta-blocker combination	Prostaglandin F receptor (FP receptor); carbonic anhydrase II; beta-adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Carbonic anhydrase inhibitor class)

1. Bausch & Lomb Incorporated · 2 drugs in this class
2. Actavis Inc. · 2 drugs in this class
3. Beijing Tiantan Hospital · 1 drug in this class
4. Merck Sharp & Dohme LLC · 1 drug in this class
5. National University Hospital, Singapore · 1 drug in this class
6. Padagis LLC · 1 drug in this class
7. Rabin Medical Center · 1 drug in this class
8. Shahid Beheshti University of Medical Sciences · 1 drug in this class
9. Sun Pharmaceutical Industries Limited · 1 drug in this class
10. University Health Network, Toronto · 1 drug in this class